Cutler Group’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-35,900
| Closed | -$21K | – | 6530 |
|
|
2021
Q3 | $21K | Buy |
35,900
+29,700
| +479% | +$3.88M | ﹤0.01% | 3327 |
|
|
2021
Q2 | $19K | Sell |
6,200
-2,800
| -31% | -$353K | ﹤0.01% | 3368 |
|
|
2021
Q1 | $48K | Buy |
+9,000
| New | +$1.16M | ﹤0.01% | 2448 |
|
|
2020
Q3 | – | Sell |
-5,300
| Closed | -$11K | – | 5465 |
|
|
2020
Q2 | $11K | Buy |
5,300
+4,000
| +308% | +$386K | ﹤0.01% | 2837 |
|
|
2020
Q1 | $14K | Buy |
+1,300
| New | +$101K | ﹤0.01% | 2545 |
|
|
2019
Q2 | – | Sell |
-3,000
| Closed | -$1K | – | 5011 |
|
|
2019
Q1 | $1K | Sell |
3,000
-10,000
| -77% | -$439K | ﹤0.01% | 3883 |
|
|
2018
Q4 | $6K | Buy |
13,000
+11,000
| +550% | +$550K | ﹤0.01% | 2879 |
|
|
2018
Q3 | $55K | Sell |
2,000
-3,000
| -60% | -$147K | ﹤0.01% | 1550 |
|
|
2018
Q2 | $54K | Buy |
+5,000
| New | +$182K | ﹤0.01% | 1563 |
|
|
2018
Q1 | – | Sell |
-2,400
| Closed | -$19K | – | 5564 |
|
|
2017
Q4 | $19K | Buy |
+2,400
| New | +$90K | ﹤0.01% | 2620 |
|
|
2017
Q3 | – | Sell |
-9,200
| Closed | -$28K | – | 7045 |
|
|
2017
Q2 | $28K | Sell |
9,200
-2,000
| -18% | -$58K | ﹤0.01% | 3084 |
|
|
2017
Q1 | $22K | Buy |
+11,200
| New | +$295K | ﹤0.01% | 3252 |
|
|
2016
Q4 | – | Sell |
-1,100
| Closed | -$1K | – | 7623 |
|
|
2016
Q3 | $1K | Hold |
1,100
| – | – | ﹤0.01% | 6408 |
|
|
2016
Q2 | $4K | Buy |
+1,100
| New | +$35.8K | ﹤0.01% | 5229 |
|
|
2016
Q1 | – | Sell |
-3,100
| Closed | -$11K | – | 7468 |
|
|
2015
Q4 | $11K | Buy |
+3,100
| New | +$112K | ﹤0.01% | 4082 |
|
Cutler Group's XLRN Position: Q4 2021 in Review
Cutler Group sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 71,931 shares — an estimated $12.4M sold.
Cutler Group first reported a position in XLRN in Q4 2015 and held it in 12 quarters. The position peaked at $12.4M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Cutler Group reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Cutler Group sold 71,931 Acceleron Pharma shares in Q4 2021, an estimated $12.4M.
- Cutler Group first reported a position in Acceleron Pharma in Q4 2015 and held it in 12 quarters.
- Cutler Group's Acceleron Pharma position peaked at $12.4M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Cutler Group's 13F filing for Q4 2021, filed 18 Jan 2022.